Christopher D Malone, Suryansh Bajaj, Aiwu He, Kabir Mody, Ryan Hickey, Ammar Sarwar, Sunil Krishnan, Tushar Patel, Beau Toskich
{"title":"结合放射栓塞和免疫检查点抑制剂治疗肝细胞癌：寻求协同作用。","authors":"Christopher D Malone, Suryansh Bajaj, Aiwu He, Kabir Mody, Ryan Hickey, Ammar Sarwar, Sunil Krishnan, Tushar Patel, Beau Toskich","doi":"10.1016/j.jvir.2024.11.012","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is a leading and increasing contributor to cancer-related death worldwide. Recent advancements in both liver-directed therapies in the form of Y-90 radioembolization (Y-90-RE) and systemic therapy in the form of immune checkpoint inhibitors (ICI) have expanded treatment options for patients with an otherwise poor prognosis. Despite these gains, ICIs and Y-90-RE each have key limitations with low objective response rates and persistent hazard of out-of-field recurrence, respectively, and overall survival remains low. However, each therapy's strength can mitigate the other's weakness, making them ideal partners for combination treatment strategies. This review discusses the scientific and clinical rationale for combining Y-90-RE with ICIs, highlights early clinical trial data on its safety and efficacy, and proposes key issues to be addressed in this emerging field. With optimal strategies, combination therapies can potentially result in durable and curative outcomes in later stage patients rarely achieved just a decade ago.</p>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Combining Radioembolization and Immune Checkpoint Inhibitors for the Treatment of Hepatocellular Carcinoma: The Quest for Synergy.\",\"authors\":\"Christopher D Malone, Suryansh Bajaj, Aiwu He, Kabir Mody, Ryan Hickey, Ammar Sarwar, Sunil Krishnan, Tushar Patel, Beau Toskich\",\"doi\":\"10.1016/j.jvir.2024.11.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Hepatocellular carcinoma (HCC) is a leading and increasing contributor to cancer-related death worldwide. Recent advancements in both liver-directed therapies in the form of Y-90 radioembolization (Y-90-RE) and systemic therapy in the form of immune checkpoint inhibitors (ICI) have expanded treatment options for patients with an otherwise poor prognosis. Despite these gains, ICIs and Y-90-RE each have key limitations with low objective response rates and persistent hazard of out-of-field recurrence, respectively, and overall survival remains low. However, each therapy's strength can mitigate the other's weakness, making them ideal partners for combination treatment strategies. This review discusses the scientific and clinical rationale for combining Y-90-RE with ICIs, highlights early clinical trial data on its safety and efficacy, and proposes key issues to be addressed in this emerging field. With optimal strategies, combination therapies can potentially result in durable and curative outcomes in later stage patients rarely achieved just a decade ago.</p>\",\"PeriodicalId\":49962,\"journal\":{\"name\":\"Journal of Vascular and Interventional Radiology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2024-11-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Vascular and Interventional Radiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jvir.2024.11.012\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Vascular and Interventional Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jvir.2024.11.012","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
Combining Radioembolization and Immune Checkpoint Inhibitors for the Treatment of Hepatocellular Carcinoma: The Quest for Synergy.
Hepatocellular carcinoma (HCC) is a leading and increasing contributor to cancer-related death worldwide. Recent advancements in both liver-directed therapies in the form of Y-90 radioembolization (Y-90-RE) and systemic therapy in the form of immune checkpoint inhibitors (ICI) have expanded treatment options for patients with an otherwise poor prognosis. Despite these gains, ICIs and Y-90-RE each have key limitations with low objective response rates and persistent hazard of out-of-field recurrence, respectively, and overall survival remains low. However, each therapy's strength can mitigate the other's weakness, making them ideal partners for combination treatment strategies. This review discusses the scientific and clinical rationale for combining Y-90-RE with ICIs, highlights early clinical trial data on its safety and efficacy, and proposes key issues to be addressed in this emerging field. With optimal strategies, combination therapies can potentially result in durable and curative outcomes in later stage patients rarely achieved just a decade ago.
期刊介绍：
JVIR, published continuously since 1990, is an international, monthly peer-reviewed interventional radiology journal. As the official journal of the Society of Interventional Radiology, JVIR is the peer-reviewed journal of choice for interventional radiologists, radiologists, cardiologists, vascular surgeons, neurosurgeons, and other clinicians who seek current and reliable information on every aspect of vascular and interventional radiology. Each issue of JVIR covers critical and cutting-edge medical minimally invasive, clinical, basic research, radiological, pathological, and socioeconomic issues of importance to the field.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
